Lilly reports 52-week results of Taltz and Zepbound in psoriatic arthritis and obesity
The company said that at one year 43.7% of patients receiving Taltz and Zepbound achieved ACR50 compared with 15.7% for Taltz alone. The 52-week Phase 3b study randomized 271 participants 1:1 to the combination or Taltz monotherapy and reported mild to moderate adverse events consistent with each drug's known safety profile.
Primary source
Company press release (PR Newswire), November 11, 2026
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity
Machine-summarized from the source above; not independently reported. How we use automation